Cannabinoids as New Medicines with Alexandros Makriyannis, PhD
Listen or watch below or subscribe on: Spotify, Apple Podcasts or YouTube.
In this episode, Dr. Alexandros Makriyannis discusses how understanding the body’s cannabinoid receptors can guide the development of new medicines for pain, obesity, and addiction. He explains how different compounds activate or block CB1 and CB2 receptors, and how mapping their three-dimensional structures helps researchers design more selective treatments. The conversation explores CB1 neutral antagonists, which aim to retain therapeutic benefits while avoiding side effects associated with earlier drugs, and CB2 agonists being investigated for inflammation and pain. He also describes findings in mice showing that blocking CB1 reduced a measure of fentanyl reward without diminishing its pain-relieving effects, while emphasizing the need for human studies. Emerging directions include comparisons with GLP-1 therapies and compounds that combine CB2 activation with CB1 blockade. A central message is that precisely targeting the endocannabinoid system may offer new treatments with fewer unwanted effects.
Dr. Alexandros Makriyannis is University Distinguished Professor, Behrakis Chair of Pharmaceutical Biotechnology, and founder and director of the Center for Drug Discovery at Northeastern University. He studied chemistry at the University of Cairo, earned his PhD in medicinal chemistry at the University of Kansas, and completed postdoctoral training at the University of California, Berkeley. His research combines medicinal chemistry and structural biology to investigate cannabinoid receptors and the enzymes that regulate the body’s own cannabinoids. His laboratory has developed widely used research compounds, and he has contributed to studies revealing the structures of CB1 and CB2 receptors. His honors include the International Cannabinoid Research Society’s Mechoulam Life Achievement Award in Cannabinoid Research, induction into the American Chemical Society’s Medicinal Chemistry Hall of Fame, and most importantly to us, the 2024 CMCR Pioneer in Medicinal Cannabis Research Award.